.svg)
Strategic Partnerships in Innovation
Nualtis collaborates with pharmaceutical companies, research institutions, and biotech innovators to advance oral film technology applications. Our partnership approach accelerates development while sharing expertise and resources for mutual success.
Trusted by Industry Innovators
Leading pharmaceutical companies and research institutions worldwide partner with Nualtis to leverage our oral film expertise, accelerate their development programs, and access cutting-edge formulation technologies for complex therapeutic challenges.
Comprehensive Partnership Models for Therapeutic Advancement
Nualtis offers flexible partnership structures designed to meet diverse pharmaceutical development needs. From licensing agreements to collaborative research programs, we provide strategic pathways that accelerate innovation and reduce development risks.
- Technology licensing with comprehensive regulatory and analytical support
- Joint development programs combining expertise and shared investment models
- Custom research services for specialized formulation and delivery challenges
Proven Track Record in Pharmaceutical Partnerships
Our partnership approach delivers measurable results through proven methodologies, technical expertise, and collaborative innovation. These outcomes demonstrate our commitment to advancing pharmaceutical development and patient care.
Explore Licensing Opportunities for Your Programs
Unlock the potential of oral film technology for your therapeutic programs through our comprehensive licensing platform. Access proven formulation expertise, regulatory support, and manufacturing capabilities to accelerate your development timeline.
Nualtis is developing a buprenorphine/naloxone sublingual film as a generic alternative for the treatment of opioid dependence. Utilizing its VersaFilm® platform, the formulation is designed to deliver reliable dosing and support patient adherence in medication-assisted treatment programs. The program aims to expand access to effective, evidence-based therapies in an established market by providing a high-quality, cost-efficient product.
Nualtis is investigating Montelukast oral film as a novel therapeutic approach for Alzheimer’s disease. Preclinical and clinical data support Montelukast’s neuroprotective and anti-inflammatory potential. The company has successfully completed a Phase 2a study, demonstrating safety and feasibility. The oral film format enhances compliance and brain bioavailability. Development is now focused on advancing clinical evaluation and strategic collaborations to position Montelukast as a promising candidate in neurodegeneration.
Nualtis is advancing the development of a tadalafil oral film, leveraging its proprietary VersaFilm® technology to deliver a discreet, convenient, and fast-acting alternative to conventional tablets. The program targets the erectile dysfunction market, where improved patient compliance and differentiated delivery formats create strong commercial potential. The oral film is designed for rapid dissolution without water, providing ease of use and portability.
Nualtis, in collaboration with Karolinska Institutet, is advancing the MONTPARK trial, a Phase 2, multicenter, randomized, double-blind, placebo-controlled study led by Professor Per Svenningsson. The 18-month trial, funded by the Swedish Research Council, is enrolling up to 90 early-to-moderate Parkinson’s patients to evaluate high-dose Montelukast VersaFilm®. The program targets neuroinflammation as a potential disease-modifying pathway, distinguishing it from existing symptomatic therapies. Results from MONTPARK will guide the clinical advancement of Nualtis’ oral film platform in neurodegeneration and position Montelukast as one of the most promising candidates in the global search for disease-modifying Parkinson’s treatments.
Begin Your Partnership Journey
Partner with Nualtis to access proven oral film technology, accelerate your development programs, and advance therapeutic innovation. Contact our partnership team to explore opportunities tailored to your specific needs and objectives.